BeBetter Med, Inc.

The treatment landscape for KRAS-mutant cancers has been rapidly evolving, with several promising advancements in recent years. The KRAS inhibitors market is expected to grow significantly in the coming years, driven by the increasing incidence of cancer and the growing demand for personalized cancer treatments, ongoing research and clinical trials have identified potential treatment strategies. LAS VEGAS, July 10, 2023 /PRNewswire/ -- DelveInsight's KRAS Inhibitors Market Insights report includes a comprehensive understanding of current treatment practices, emerging KRAS inhibitors, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]. Key Takeaways from the KRAS Inhibitors Market Report As per DelveInsight analysis, the KRAS inhibitors market size in the 7MM was approximately USD ~240 million in 2022. According to the assessment done by DelveInsight, the total KRAS-mutated cases in the 7MM comprised more than ~ 490,000 cases in 2022 and are projected to increase during the forecast period. Leading inhibitors companies such as Novartis, Roche, Genentech, Verastem Oncology, Revolution Medicines, Cardiff Oncology, Immuneering Corporation, Jacobio Pharmaceuticals, BridgeBio Pharma, Mirati Therapeutics, Deciphera Pharmaceuticals, Elicio Therapeutics, InventisBio, Gritstone Bio, D3 Bio, and others are developing novel KRAS inhibitors that can be available in the KRAS inhibitors market in the coming years. The promising KRAS inhibitors in the pipeline include JDQ443, Divarasib, Avutometinib (VS-6766), RMC-4630, Onvansertib, IMM-1-104, Glecirasib (JAB-21822), BBP-398, MRTX1133, DCC-3116, ELI-002, D-1553, SLATE-KRAS, D3S-001, and others. Discover which therapies are expected to grab the major KRAS inhibitors market share @ KRAS Inhibitors Market Report KRAS Inhibitors Overview KRAS is a member of the RAS superfamily of small GTP-binding proteins known as RAS-like GTPases. The oncogene rat sarcoma virus (RAS) acts as a signal transducer, influencing cell proliferation, differentiation, and survival in both normal and malignant cells. The most often mutated RAS gene is KRAS, followed by NRAS and HRAS. The human KRAS gene is found on chromosome 12p12.1. It is encoded by six exons, which are positioned at locations 12 and 13 in exon 1 and, less commonly, at codons 61, 63, 117, 119, and 146. KRAS mutations can be identified through genetic sequencing of tumor tissue or through the use of a liquid biopsy. KRAS testing requests for patients are often initiated by the doctor. Typically, the examination is done on tumor tissue extracted from the patient through a previous surgery or biopsy operation. Adjuvant therapy is usually required for patients having KRAS testing who have advanced tumors. KRAS Inhibitors Epidemiology Segmentation DelveInsight estimates that there were approximately ~ 490,000 total KRAS-mutated cases in the 7MM in 2022. KRAS mutations are seen most frequently in pancreatic cancer, followed by CRC and NSCLC. The most frequent KRAS variant observed in NSCLC is G12C. In addition, the most common KRAS variation in CRC and pancreatic cancer is G12D. In the United States, KRASG12C is present in ~37% of NSCLC cases. The highest rates of KRASG12D, i.e., ~42% and 30%, were found in pancreatic cancer and CRC, respectively. The KRAS inhibitors market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into: Total Incident Cases of NSCLC, CRC, and Pancreatic Cancer Total KRAS Incident Cases in NSCLC, CRC, and Pancreatic Cancer Total KRAS Variant Cases in NSCLC, CRC, and Pancreatic Cancer KRAS Inhibitors Treatment Market Treatment choices for KRAS-mutant cancer are determined on the type of cancer, stage of the disease, and individual patient factors. The treatment landscape for KRAS-mutated cancer has been evolving. Chemotherapy drugs such as platinum-based agents (cisplatin, carboplatin), taxanes (paclitaxel, docetaxel), and others may be used to treat KRAS-mutant tumors. Chemotherapy is frequently used in conjunction with other treatments, such as targeted therapies or immunotherapies. Certain targeted therapy may be used depending on the type of cancer and the concomitant genetic changes. In colon cancer with KRAS mutations, for example, anti-EGFR antibodies (cetuximab, panitumumab) may be administered if the KRAS mutation is wild-type at codons 12 and 13. In some circumstances, alternative targeted treatments that inhibit downstream signaling pathways (such as MEK inhibitors) or angiogenesis pathways (such as anti-VEGF therapies) may be considered. Immune checkpoint inhibitors, such as pembrolizumab and nivolumab, and CTLA-4 inhibitors (ipilimumab), have transformed cancer treatment. While immunotherapy may not directly target KRAS mutations, it can improve the immune system's ability to identify and fight cancer cells. For KRAS-mutant tumors, clinical trials are looking into combining immunotherapy with other targeted medicines like chemotherapy. The FDA granted accelerated clearance to LUMAKRAS (sotorasib, Amgen) in May 2021 for the treatment of people with advanced non-small cell lung cancer (NSCLC) who have a KRAS G12C mutation and have had at least one prior systemic therapy. The FDA granted accelerated approval for KRAZATI (adagrasib) in December 2022, a targeted treatment option for adult patients with KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), as determined by an FDA-approved test, who have received at least one prior systemic therapy. Mirati filed a Marketing Authorization Application (MAA) in the EU in May 2022. To know more about KRAS inhibitors, visit @ KRAS Inhibitors Treatment Key KRAS Inhibitors Therapies and Companies JDQ443: Novartis Divarasib: Roche/Genentech Avutometinib (VS-6766): Verastem Oncology RMC-4630: Revolution Medicines Onvansertib: Cardiff Oncology IMM-1-104: Immuneering Corporation Glecirasib (JAB-21822): Jacobio Pharmaceuticals BBP-398: BridgeBio Pharma (Navire Pharma) MRTX1133: Mirati Therapeutics DCC-3116: Deciphera Pharmaceuticals ELI-002: Elicio Therapeutics D-1553: InventisBio SLATE-KRAS: Gritstone Bio D3S-001: D3 Bio Learn more about the FDA-approved KRAS inhibitors @ KRAS Inhibitors Drugs KRAS Inhibitors Market Dynamics The dynamics of the KRAS inhibitors market are anticipated to change in the coming years. Historically, KRAS mutations were thought to be difficult to target, and effective treatments for KRAS-mutant tumors were scarce. As a result, there is a substantial unmet need for effective therapies, resulting in high KRAS inhibitors market demand. In addition, research advances have led to the identification of possible treatment targets and techniques for KRAS-mutant malignancies. The continued development of targeted therapies, such as KRAS-G12C and Pan-KRAS inhibitors, provides a considerable KRAS inhibitors market opportunity. However, despite decades of research, there have been few viable tactics for targeting KRAS mutations, with the exception of recent breakthroughs like sotorasib and adagrasib, which have been approved to target a specific mutant version of KRAS known as KRAS (G12C). Because of its inherent properties, specifically targeting KRAS has proven to be a hard challenge. As a result, scientists have looked into alternative tactics such as targeting downstream signaling molecules, using epigenetic methods such as telomerase inhibitors and RNA interference, and adopting synthetic lethality procedures involving cyclin-dependent kinase inhibitors. Furthermore, as our understanding of KRAS biology grows, more companies and institutions are entering the sector to explore therapeutics for KRAS-mutant malignancies. The KRAS inhibitors market may grow highly competitive, with numerous companies contending for KRAS inhibitors market share. Moreover, Amgen and Mirati Therapeutics are at the forefront of the race to discover KRAS inhibitors for cancer treatment. However, their present prospects are mainly focused on G12C-mutant tumors, leaving a major gap in tackling other KRAS variations. This represents a significant unmet need in the profession, given no approved treatments are currently available for other variations. Recognizing this difficulty, multiple prominent players are currently investigating alternate KRAS variations and expanding their research to cover tumors other than NSCLC. This shift in focus has the potential to lead to the development of successful medicines that can address a broader spectrum of KRAS mutations and target numerous cancer types. Scope of the KRAS Inhibitors Market Report Therapeutic Assessment: KRAS Inhibitors current marketed and emerging therapies KRAS Inhibitors Market Dynamics: Attribute Analysis of Emerging KRAS Inhibitors Drugs Competitive Intelligence Analysis: SWOT analysis and Market entry strategies Unmet Needs, KOL's Views, Analyst's Views, KRAS Inhibitors Market Access and Reimbursement Discover more about KRAS inhibitors drugs in development @ KRAS Inhibitors Clinical Trials Table of Contents Related Reports JAK Inhibitors Competitive Landscape JAK Inhibitors Competitive Landscape – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key JAK inhibitors companies, including Pfizer, Sierra Oncology, Theravance Biopharma, Dizal Pharmaceutical, Aclaris Therapeutics, Celon Pharma, Incyte Corporation, AbbVie, Galapagos, among others. TIGIT Inhibitors Competitive Landscape TIGIT Inhibitors Competitive Landscape – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key TIGIT inhibitors companies, including Merck Sharp & Dohme, Bristol-Myers Squibb, BeiGene, Arcus Biosciences, iTeos Therapeutics, Mereo BioPharma, Phio Pharmaceuticals, Bio-Thera Solutions, Compugen, among others. Checkpoint Inhibitors Competitive Landscape Checkpoint Inhibitors Competitive Landscape – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key checkpoint inhibitors companies, including BeBetter Med, BIOCAD, CanBas Co., Ltd., Laekna Therapeutics, Genentech, Alphamab Oncology, Hangzhou Sumgen Biotech, Harbour BioMed, Aurigene Discovery Technologies, BeiGene, Apollomics, BCN Biosciences, Phio Pharmaceuticals, Atridia, Jiangsu HengRui Medicine, EMD Serono, Innovent Biologics, Agenus, among others. PD-1 and PD-L1 Inhibitors Competitive Landscape PD-1 and PD-L1 Inhibitors Competitive Landscape – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key PD-1 and PD-L1 inhibitors companies, including Merck, Laekna Therapeutics, Genentech, Tracon Pharmaceuticals Inc., Celgene, MedImmune, Hangzhou Sumgen Biotech, among others. About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve . Contact Us Shruti Thakur [email protected] +1(919)321-6187 Logo: SOURCE DelveInsight Business Research, LLP

Global Premier Fertility claims to protect physicians as equity partners and to help them maintain influence over key decision-making. Over the past few years, investors from Morgan Stanley to Lee Equity have turned their attention to fertility clinics. They say their goal is to enable quality care under business growth. The majority of in vitro fertilization clinics are now privately owned, with the market currently worth about $8 billion, according to one estimate. More employers are looking to offer fertility benefits in a booming market for the services. Analysts estimate the industry to reach $41 billion by 2026. Last year alone, fertility support startups raised $345 million in venture capital, more than double since 2019. Interest in women’s health more broadly is also piquing, with startups in the area landing a whopping $1.4 billion in funding last year.  Yet growing criticism of private equity investment in healthcare argues it leads to market consolidation, higher costs, diminished physician ownership and even worse outcomes. Kolin Ozonian, founder and CEO of Global Premier Fertility, which builds, acquires and manages clinics, believes the traditional investor approach has been “very damaging to patient care.” Ozonian managed operations for a division of one of the largest networks of fertility care providers in the U.S., IntegraMed, before it went bankrupt in 2020. The company was owned by a private equity fund and allegedly owed fertility patients millions of dollars, which it had misappropriated, lawyers reportedly said.  At his division, IntegraMed Fertility, Ozonian experienced a trickle-down pressure that prioritized return on investment, he told Fierce Healthcare. Regular assessments of whether a clinic was profitable led to pushes on physicians to recommend high-cost procedures, even when they were not needed, Ozonian recalled. In other instances, physicians were asked to spend less face time with patients to squeeze more appointments in daily. “That’s absurd to me,” Ozonian said. Though the company promised employees higher bonuses or wages if they could hit certain targets, he said, providers are “not incentivized by that.”   Determined to build a better approach, Ozonian founded Global Premier Fertility, which operates on a partnership model. The company, of which Ozonian is CEO, claims to protect physicians as equity partners and says it allows them to maintain influence over key decision-making. It also aims to loop in younger physicians who are eager to revolutionize the fertility space. “It’s all about culture,” Ozonian said.  By providing fundamental management services while creating growth opportunities for younger physicians, Global Premier Fertility has developed an innovative and collaborative partnership model that disrupts the old-school arrangement between investors and their network of providers, according to Ozonian. The result, he says, is that physicians with an impressive assortment of reproductive expertise are joining Global Premier Fertility and bringing fresh, new ideas to today's fertility challenges. Luis Murrain, D.O., a reproductive genetics specialist and partner physician at a Global Premier facility in Palm Springs, California, agrees. In his past work in a small practice setting, Murrain recalled physicians beginning as junior associates and spending years working up to partnership status, granted only after meeting certain quotas. Operational tasks were split between physicians at the practice, diverting their resources away from patient care.  An approach like Global Premier’s enables Murrain to participate in a “fairly unique physician partnership model and that allows us to focus on patient-first experience,” Murrain told Fierce Healthcare. The company also claims not to pass significant costs onto practices.   In June, Global Premier Fertility raised $11 million in a series C funding round, with a commitment of an additional future $50 million. Several of the company’s clinics based in southern California are focused on serving the LGBTQ+ population, training their clinicians on how to provide non-stigmatizing care. The goal, the head of referral development previously told Fierce Healthcare, is to establish trust with a patient. Trust is possible through things like gender-affirming pronouns and an understanding of the unique challenges the population faces, like discrimination.  To find a buyer with interests aligned with those of a practice, it’s important to invest in a representative—like an investment banker—who understands your mission, the industry and can ask buyers tough questions, explained Isabelle Bibet-Kalinyak, a healthcare attorney at New Jersey-based law firm Brach Eichler. Bibet-Kalinyak has represented providers on the seller side.  The advantage of selling to private equity, she said, is the access to capital. Fertility practices can be hard to scale for a number of reasons; an investor can bring cash and operational know-how that physicians might not necessarily have.  “They’re doctors. They’re not trained to be business people,” Bibet-Kalinyak said. “The inefficiencies in healthcare are tremendous.” Investors try to eliminate those to generate a more healthy balance sheet, she added.  There are numerous downsides to a private equity buyer, however. A deal means employees must stay at the company for a number of years if they want to get rollover equity. A buyer could also not be amenable to adjusting a contract—that’s a red flag, according to Bibet-Kalinyak. A buyer should never go against clinical judgment. And one must not be blinded by the promise of equity, she added. Practices should look for strategic partners that focus on the provider's specialty and on delivering better care. The more the buyer works like a strategic partner, "the more it’s going to be personal," she said. “You have to negotiate hard and put things in writing,” Bibet-Kalinyak said. “If you don’t like the terms, walk away.”